Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRI
Biofrontera
$1.04
-3.7%
$0.75
$0.54
$2.22
$10.95M0.43176,627 shs71,638 shs
Clene Inc. stock logo
CLNN
Clene
$3.49
-1.4%
$3.82
$2.28
$6.96
$29.27M0.5555,384 shs362,287 shs
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$1.11
-4.7%
$1.62
$1.05
$4.40
$26.85M1.3146,174 shs24,881 shs
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$3.36
-2.9%
$2.83
$0.36
$10.00
$31.81MN/A54,733 shs29,375 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRI
Biofrontera
-3.70%-1.89%+50.70%+44.44%-13.33%
Clene Inc. stock logo
CLNN
Clene
-1.41%-4.38%-11.65%+17.11%-23.30%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-4.72%-23.97%-27.92%-39.01%+110,999,900.00%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
-2.89%-11.35%+3.70%+57.75%+3,260.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biofrontera Inc. stock logo
BFRI
Biofrontera
1.6918 of 5 stars
3.53.00.00.00.60.00.6
Clene Inc. stock logo
CLNN
Clene
3.4949 of 5 stars
3.65.00.00.02.72.50.6
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
3.8798 of 5 stars
3.80.00.00.03.33.31.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera Inc. stock logo
BFRI
Biofrontera
3.00
Buy$2.75164.42% Upside
Clene Inc. stock logo
CLNN
Clene
3.17
Buy$40.001,046.13% Upside
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
0.00
N/AN/AN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
3.50
Strong Buy$10.00197.62% Upside

Current Analyst Ratings Breakdown

Latest BFRI, SNYR, CLNN, and RNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Clene Inc. stock logo
CLNN
Clene
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
6/30/2025
Clene Inc. stock logo
CLNN
Clene
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
5/19/2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $2.75
5/8/2025
Clene Inc. stock logo
CLNN
Clene
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$84.00 ➝ $33.00
5/8/2025
Clene Inc. stock logo
CLNN
Clene
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera Inc. stock logo
BFRI
Biofrontera
$38.00M0.28N/AN/A$0.57 per share1.82
Clene Inc. stock logo
CLNN
Clene
$340K84.89N/AN/A($1.06) per share-3.29
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/A$0.43 per share2.60$0.43 per shareN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$34.83M0.89$0.26 per share13.01($1.91) per share-1.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$17.76M-$2.26N/AN/AN/A-30.33%-305.13%-82.67%8/13/2025 (Estimated)
Clene Inc. stock logo
CLNN
Clene
-$39.40M-$4.04N/AN/AN/A-8,306.00%N/A-105.11%8/6/2025 (Estimated)
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$62.88M-$2.86N/AN/AN/AN/A-86.07%-31.11%N/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$2.12MN/A0.005.69N/AN/A-8.48%12.75%N/A

Latest BFRI, SNYR, CLNN, and RNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$0.45N/AN/AN/A$8.30 millionN/A
8/6/2025Q2 2025
Clene Inc. stock logo
CLNN
Clene
-$0.49N/AN/AN/A$0.06 millionN/A
5/15/2025Q1 2025
Biofrontera Inc. stock logo
BFRI
Biofrontera
-$0.14-$0.47-$0.33-$0.47$10.55 million$8.59 million
5/15/2025Q1 2025
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$0.21-$0.25-$0.04-$0.25N/AN/A
5/15/2025Q1 2025
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
$0.07$0.10+$0.03$0.10$9.03 million$8.17 million
5/7/2025Q1 2025
Clene Inc. stock logo
CLNN
Clene
-$1.10-$0.50+$0.60-$0.09$0.07 million$0.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera Inc. stock logo
BFRI
Biofrontera
N/AN/AN/AN/AN/A
Clene Inc. stock logo
CLNN
Clene
N/AN/AN/AN/AN/A
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera Inc. stock logo
BFRI
Biofrontera
8.99
1.40
0.80
Clene Inc. stock logo
CLNN
Clene
N/A
1.36
1.36
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/A
1.39
1.39
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/A
1.91
1.62

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera Inc. stock logo
BFRI
Biofrontera
10.08%
Clene Inc. stock logo
CLNN
Clene
23.28%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
90.89%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
N/A

Insider Ownership

CompanyInsider Ownership
Biofrontera Inc. stock logo
BFRI
Biofrontera
1.20%
Clene Inc. stock logo
CLNN
Clene
35.30%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
5.10%
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
56.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera Inc. stock logo
BFRI
Biofrontera
7010.14 million10.02 millionNo Data
Clene Inc. stock logo
CLNN
Clene
1008.27 million5.35 millionOptionable
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
923.05 million21.02 millionN/A
Synergy CHC Corp. stock logo
SNYR
Synergy CHC
409.19 million3.99 millionN/A

Recent News About These Companies

SNYR Synergy CHC Corp.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRI

$1.04 -0.04 (-3.52%)
As of 08/1/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Clene stock logo

Clene NASDAQ:CLNN

$3.49 -0.05 (-1.41%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.48 -0.01 (-0.14%)
As of 08/1/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Rein Therapeutics stock logo

Rein Therapeutics NASDAQ:RNTX

$1.11 -0.06 (-4.72%)
As of 08/1/2025 03:59 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Synergy CHC stock logo

Synergy CHC NASDAQ:SNYR

$3.36 -0.10 (-2.89%)
As of 08/1/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.